New program seeks to expand access to patients suffering from multiple sclerosis (MS)
NEWTOWN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its Patient Therapy Access Program (“PTAP”), which will provide qualifying patients access to on-label Portable Neuromodulation Stimulator (“PoNS”) Therapy at a significantly reduced price. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from multiple sclerosis (“MS”) and is available by prescription only.
“In April, we announced that the first patients in the United States had purchased the PoNS device on a cash pay basis and begun treatment. We are also offering an opportunity for MS patients to be treated with PoNS Therapy™ through our previously announced Therapeutic Experience Program (“TEP”), gathering important clinical evidence in a real-world environment while we pursue reimbursement from third-party payers and CMS. Our goal is to bring treatment to as many qualifying patients as possible and we are proud to introduce our Patient Therapy Access Program for potential first-time users,” stated Dane Andreeff, President and Chief Executive Officer of Helius.
“With the proper prescription and a letter of medical necessity, people struggling with MS in the U.S. will be able to access PoNS Therapy at a greatly reduced price. We believe this program will accelerate the adoption of PoNS Therapy and help to establish PoNS as the standard of care for MS patients with gait deficit. PTAP participants will also be invited to join Helius’s upcoming registry program, which is designed to collect important health economic information to establish the value of PoNS on key therapeutic outcomes and will complement the data gleaned through TEP,” concluded Mr. Andreeff.
The PTAP is currently available and expected to run through December 31, 2022.
Recent HSDT News
- Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024 • GlobeNewswire Inc. • 05/10/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:31:03 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/08/2024 08:56:46 PM
- Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering • GlobeNewswire Inc. • 05/07/2024 02:15:00 AM
- Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®) • GlobeNewswire Inc. • 05/06/2024 01:00:00 PM
- Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center • GlobeNewswire Inc. • 04/24/2024 01:05:00 PM
- Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™ • GlobeNewswire Inc. • 04/03/2024 11:05:00 AM
- Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 08:05:00 PM
- Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 • GlobeNewswire Inc. • 03/15/2024 11:05:00 AM
- Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke • GlobeNewswire Inc. • 03/12/2024 12:59:22 PM
- Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:30:51 PM
- Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller • GlobeNewswire Inc. • 03/04/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:09:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:15:49 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:22:13 PM
- Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients • GlobeNewswire Inc. • 02/06/2024 12:00:00 PM
- Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS • GlobeNewswire Inc. • 02/05/2024 12:05:00 PM
- Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital • GlobeNewswire Inc. • 01/11/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 02:00:31 PM
- Helius Medical Technologies to Present at NobleCon19 Annual Conference • GlobeNewswire Inc. • 11/30/2023 12:47:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:22 PM
- Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
- Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work • GlobeNewswire Inc. • 11/06/2023 12:05:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM